Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia
Journal
Blood
Journal Volume
121
Journal Issue
16
Pages
3172
Date Issued
2013-04-18
Author(s)
Lee, Ming-Cheng
Liu, Chieh-Yu
Jhuang, Jie-Yang
Lai, Yan-Jun
Chen, Huan-Yuan
Liu, Fu-Tong
Abstract
Alterations of galectin-3 expression are often seen in cancers and may contribute to tumorigenesis, cancer progression, and metastasis. The studies concerning clinical implications of galectin-3 expression in patients with acute myeloid leukemia (AML) are scarce. We investigated the expression of LGALS3, the gene encoding galectin-3, in the bone marrow (BM) mononuclear cells from an original cohort comprising 280 adults with primary non-acute promyelocytic leukemia. Higher LGALS3 expression was closely associated with older age, French-American-British M4/M5 subtypes, CD14 expression on leukemic cells, and PTPN11 mutation, but negatively correlated with CEBPA mutation and FLT3-ITD. Compared with patients with lower LGALS3 expression, those with higher expression had lower complete remission rates, higher primary refractory rates, and shorter overall survival. This result was validated in an independent validation cohort. A scoring system incorporating higher LGALS3 expression and 8 other risk factors, including age, white blood cell count, cytogenetics, and gene mutations, into survival analysis proved to be very useful to stratify patients with AML into different prognostic groups (P < .001). In conclusion, BM LGALS3 expression may serve as a new biomarker to predict clinical outcome in patients with AML, and galectin-3 may serve as a potential therapeutic target in those patients with higher expression of this protein.
Other Subjects
CCAAT enhancer binding protein alpha; CD11b antigen; CD135 antigen; CD14 antigen; CD15 antigen; CD19 antigen; CD2 antigen; CD20 antigen; CD33 antigen; CD34 antigen; CD5 antigen; CD56 antigen; CD7 antigen; common acute lymphoblastic leukemia antigen; cytarabine; galectin 3; HLA DR antigen; idarubicin; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; lgals 3 protein; microsomal aminopeptidase; mitoxantrone; nucleophosmin; peptides and proteins; peroxidase; protein tyrosine phosphatase SHP 2; Ras protein; transcription factor RUNX1; unclassified drug; WT1 protein; galectin 3; RNA; acute myeloid leukemia; adolescent; adult; aged; allogeneic hematopoietic stem cell transplantation; Article; bone marrow; cancer patient; cancer prognosis; cancer regression; cancer survival; cancer therapy; clinical outcome; comorbidity; consolidation chemotherapy; cytogenetics; disease free survival; drug megadose; enzyme linked immunosorbent assay; female; follow up; gene mutation; human; immunohistochemistry; immunophenotyping; induction chemotherapy; leukocyte count; major clinical study; male; multiple cycle treatment; overall survival; priority journal; prognostic assessment; protein determination; protein expression; respiratory quotient; risk factor; scoring system; acute granulocytic leukemia; article; bone marrow; cohort analysis; gene expression; genetics; karyotype; metabolism; middle aged; mutation; pathology; prognosis; survival; treatment outcome; upregulation; very elderly; Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow; Cohort Studies; Female; Galectin 3; Gene Expression; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; RNA; Survival Analysis; Treatment Outcome; Up-Regulation; Young Adult
Publisher
AMER SOC HEMATOLOGY